Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inmune Bio (INMB) Non-Current Assets (2017 - 2025)

Inmune Bio's Non-Current Assets history spans 9 years, with the latest figure at $2.7 million for Q3 2025.

  • For Q3 2025, Non-Current Assets fell 84.12% year-over-year to $2.7 million; the TTM value through Sep 2025 reached $38.1 million, down 43.97%, while the annual FY2024 figure was $16.9 million, 0.93% down from the prior year.
  • Non-Current Assets for Q3 2025 was $2.7 million at Inmune Bio, up from $1.6 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $17.3 million in Q4 2021 and bottomed at $1.6 million in Q2 2025.
  • The 5-year median for Non-Current Assets is $17.0 million (2024), against an average of $15.4 million.
  • The largest annual shift saw Non-Current Assets rose 4.01% in 2021 before it plummeted 90.27% in 2025.
  • A 5-year view of Non-Current Assets shows it stood at $17.3 million in 2021, then fell by 1.26% to $17.1 million in 2022, then dropped by 0.36% to $17.1 million in 2023, then decreased by 0.93% to $16.9 million in 2024, then plummeted by 84.09% to $2.7 million in 2025.
  • Per Business Quant, the three most recent readings for INMB's Non-Current Assets are $2.7 million (Q3 2025), $1.6 million (Q2 2025), and $16.8 million (Q1 2025).